SOX4 as a potential therapeutic target for pathological cardiac hypertrophy

Area of Science:

• Cardiology
• Molecular Biology
• Biochemistry

Background:

• Pathological cardiac hypertrophy is a precursor to heart failure, necessitating preventative strategies.
• The role of SOX4 (SRY-box 4), a transcription factor, in cardiac hypertrophy remains largely undefined.
• Understanding molecular mechanisms driving cardiac hypertrophy is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role and mechanism of SOX4 in pathological cardiac hypertrophy.
• To determine if SOX4 influences oxidative stress pathways in cardiomyocytes.
• To evaluate SOX4 as a potential therapeutic target for cardiac hypertrophy.

Main Methods:

• Assessed SOX4 expression in hypertrophic heart models and angiotensin II-treated neonatal rat cardiomyocytes (NRCMs).
• Utilized knockdown techniques for SOX4 in NRCMs and mouse hearts to assess hypertrophic responses.
• Investigated the molecular interaction between SOX4 and the SIRT3 promoter using molecular biology assays.
• Measured reactive oxygen species (ROS) and MnSOD acetylation levels to assess oxidative stress.

Main Results:

• SOX4 expression was significantly upregulated in hypertrophic hearts and Ang II-stimulated NRCMs.
• Knockdown of SOX4 attenuated cardiac hypertrophy in both cellular and in vivo models.
• SOX4 directly binds to the SIRT3 promoter, suppressing its transcription and expression.
• SOX4 inhibition led to reduced MnSOD acetylation, decreased ROS production, and mitigated oxidative stress.

Conclusions:

• SOX4 plays a critical role in promoting pathological cardiac hypertrophy.
• The mechanism involves SOX4-mediated repression of SIRT3, leading to increased oxidative stress.
• Targeting SOX4 presents a promising therapeutic avenue for treating cardiac hypertrophy and preventing heart failure.